Robert Malenka Sells 11,264 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 11,264 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $18.42, for a total transaction of $207,482.88. Following the transaction, the director directly owned 325,795 shares in the company, valued at $6,001,143.90. This trade represents a 3.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Maplight Therapeutics Price Performance

Shares of MPLT opened at $17.63 on Thursday. The stock has a 50 day simple moving average of $17.79. Maplight Therapeutics, Inc. has a fifty-two week low of $12.24 and a fifty-two week high of $21.55. The stock has a market cap of $799.87 million and a PE ratio of -0.47.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

Several research analysts have recently commented on MPLT shares. Wall Street Zen raised Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Morgan Stanley began coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price for the company. Leerink Partners initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “outperform” rating and a $30.00 price target on the stock. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. Finally, Jefferies Financial Group began coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $32.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Maplight Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Institutional Trading of Maplight Therapeutics

Several large investors have recently bought and sold shares of the stock. Fcpm Iii Services B.V. acquired a new position in Maplight Therapeutics during the 4th quarter valued at approximately $56,672,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Maplight Therapeutics during the fourth quarter valued at $49,154,000. Goldman Sachs Group Inc. acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $34,026,000. Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics in the 4th quarter worth $17,060,000. Finally, 5AM Venture Management LLC acquired a new stake in Maplight Therapeutics during the 4th quarter worth about $16,687,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.